Bookmark

Add to MyYahoo RSS

CGI Pharmaceuticals News

News on CGI Pharmaceuticals (Ticker: GILD) continually updated from thousands of sources around the net.

Saturday | The Motley Fool

This Week in Biotech: Puma Sprints, Gilead Sweeps, and Inovio Hits the Mark

With the SPDR S&P Biotech Index up 22% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Science / Technology, Startups, Healthcare Law, Food and Drug Administration, Law

Fri Jul 25, 2014

Customer Interaction Solutions

European CHMP Adopts Positive Opinion for Gilead's Zydelig...

Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use , the scientific committee of the European Medicines Agency , has adopted a positive opinion on the company's Marketing Authorization Application for Zydelig , a first-in-class treatment for patients with chronic lymphocytic leukemia and follicular ... (more)

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Marketing, Leukemia, Health, Lymphoma

Thu Jul 24, 2014

Trader Mike

STTG Market Recap July 23, 2014

Indexes were up most of the session as a surge by Apple helped lift things; this is a massive component of the NASDAQ.

Comment?

Related Topix: Apple, Startups, Biotech, Medicine, Gilead Sciences, Healthcare Industry

AmericanBankingNews.com

Gilead Sciences (GILD) Releases Quarterly Earnings, Beats Estimates By $0.63 EPS

Gilead Sciences released its earnings data on Wednesday. The company reported $2.36 earnings per share for the quarter, beating the analysts' consensus estimate of $1.73 by $0.63, American Banking News.com reports.

Comment?

Related Topix: Biotech, Startups, Medicine, Gilead Sciences, Healthcare Industry

Wed Jul 23, 2014

Customer Interaction Solutions

Gilead Announces New Agreement with Medicines Patent Pool for Access...

Gilead Sciences, Inc. announced today at the 20th International AIDS Conference in Melbourne, Australia, a new agreement with the Medicines Patent Pool to expand access to Gilead's investigational drug tenofovir alafenamide for HIV and hepatitis B, contingent on the medicine's U.S. regulatory approval.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, HIV/AIDS, Health, Startups, Australia, World News, Viread, Tenofovir (generic)

BioSpace

U.S. FDA Approves Gilead Sciences, Inc.'s Zydelig (idelalisib)...

U.S. FDA Approves Gilead Sciences, Inc. 's Zydelig For Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma And Small Lymphocytic Lymphoma U.S. FDA Approves FDA's ZydeligA For Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma And Small Lymphocytic Lymphoma 82 Percent Reduction in Risk of Disease Progression or Death When Combined ... (more)

Comment?

Related Topix: Biotech, Healthcare Law, Medicine, Law, Gilead Sciences, Healthcare Industry, Food and Drug Administration, Startups, Lymphoma, Health

Freshnews

Gilead Sciences Announces Second Quarter 2014 Financial Results

Gilead Sciences, Inc. announced today its results of operations for the quarter ended June 30, 2014.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Marketing

SFGate

Will controversial hepatitis C drug continue its blockbuster sales?

Gilead Sciences' $1,000-a-day hepatitis C pill is facing a firestorm of criticism from insurers and lawmakers, but none of those obstacles are likely to stop the Foster City company from reporting blockbuster revenues during the second quarter today.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Hepatitis, Health, Startups, Liver Cancer

Tue Jul 22, 2014

SFGate

Netflix falls on lower quarterly forecast

That's how much Netflix shares dropped on Tuesday after the streaming-video company forecast a profit of 89 cents a share, falling short of the $1.02 projected by analysts.

Comment?

Related Topix: Netflix, Startups, Biotech, Medicine, Gilead Sciences, Healthcare Industry, San Mateo County, CA, Foster City, CA

Mon Jul 21, 2014

SFGate

Costly hepatitis C drugs could add $300 to every American's yearly premium, CVS says

Gilead Sciences' new hepatitis C drug receives as much praise for its healing powers as it receives criticism of its price, $84,000 for 12 weeks.

Comment?

Related Topix: Hepatitis, Medicine, Health, Biotech, Gilead Sciences, Healthcare Industry, Retail, CVS, Startups

Seeking Alpha

Biotechs Have Their 'Irrational Exuberance' Moment: Time To Buy More?

Background : When the Fed noted some froth in "smaller" biotechs last week, large ones also got slammed.

Comment?

Related Topix: Biotech, Biogen Idec, Startups, Medicine, Gilead Sciences, Healthcare Industry, Financial Markets, Amgen

Thu Jul 17, 2014

SFGate

Could California spend $6.7 billion for hepatitis C drug?

This undated handout photo provided by Gilead Sciences shows the Hepatitis-C medication Sovaldi.

Comment?

Related Topix: Hepatitis, Medicine, Health, Biotech, Gilead Sciences, Healthcare Industry, Startups, Medicaid, Express Scripts

Wed Jul 16, 2014

Investor's Business Daily

Gilead Sciences to Release Second Quarter 2014 Financial Results on...

Gilead Sciences, Inc. announced today that its second quarter 2014 financial results will be released on Wednesday, July 23, at 4:05 p.m. Eastern Time.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups

Fri Jul 11, 2014

Inside Bay Area

U.S. senators ask Gilead Sciences to explain high cost of hepatitis C drug

Two U.S. senators asked Gilead Sciences Inc. to produce documents explaining why its new hepatitis C drug is priced at $84,000, raising renewed concerns over the high costs to taxpayers.

Comment?

Related Topix: Gilead Sciences, Biotech, Medicine, Healthcare Industry, Hepatitis, Health, Startups, US News, US Senate, Ron Wyden, Democrat, US Politics, Republican, Chuck Grassley

InvestorIdeas.com

Turnaround Stories Lead Reni Benjamin's Biotech Front-Runners

July 11, 2014 The biotech bull market is not over. That's the judgment of Reni Benjamin of H.C. Wainwright & Co., who predicts high quality data from a broad range of small- and mid-cap biotechs will move shares higher during the summer and especially in the fall.

Comment?

Related Topix: Biotech, Science / Technology, Gilead Sciences, Healthcare Industry, Startups, Merck

Thu Jul 10, 2014

Seeking Alpha

A Pre-Earnings Update On Gilead

Background : Gilead Sciences may remain substantially undervalued relative to the market despite its tremendous stock price appreciation recently and over many years.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Genetics, Bristol Myers Squibb

Wed Jul 09, 2014

Forbes.com

Gilead Sciences Moves Up In Market Cap Rank, Passing PepsiCo

Market capitalization is an important data point for investors to keep an eye on, for various reasons.

Comment?

Related Topix: Beverages, PepsiCo, Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Financial Markets

Wed Jul 02, 2014

GlobeNewswire

Strong IPO Market for Life Sciences Companies Defines First Half of 2014

Life sciences companies raised $4.7 billion globally in 68 initial public offerings during the first half 2014, exceeding the 66 life sciences IPOs completed in all of 2013.

Comment?

Related Topix: Biotech, Science / Technology, Circassia, Financial Markets, Startups, Gilead Sciences

Mon Jun 30, 2014

Wall St. Cheat Sheet

Why Gilead Sciences Is a Must-Own Stock

Gilead Sciences Inc . is one of my top choices for any stocks moving forward through 2014 into 2015.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••